Background: STDs are increasing and control of HIV infection is getting better. Our aim was to determine if the combined use of calcitonin and etidronate influences bone mass loss.
Methods: We studied for 12 months 21 women who were 42 to 57 years old and had a bone mineral density at the lumbar spine between 146 mg/cc and 75 mg/cc, 10 were assigned to 10 mg of etidronate. Eleven were treated with 10 mg of etidronate and 200 UI of intranasal calcitonin.
Results: Mean mineral bone density at the lumbar spine was between -1 and -3 DS below the mean value for premenopausal women. After a treatment of 12 months no statistical significance difference was found among both groups as for the bone mineral density at the lumbar spine.
Conclusions: It is necessary to carry out a wider and longer study, among VIH-patients, but it seems that etidronate contribute advantages to decrease bone mass loss, at least, at lumbar spine, without calcitonin. This results can be interesting for VIH-infected, who are on a lot of medication and with ancient, actual and future sexual issues in relation to osteoporosis.
Disclosure: The authors declared no competing interests.